Uso del Tratamiento Biológico en pacientes con Psoriasis
Psoriasis is a chronic erythematous scaly disease of the skin, characterized by excessive hyperproliferation of epidermal keratinocytes and infiltration of the skin by inflammatory cells. Its cause is multifactorial: genetic predisposition triggered by an environmental stimulus, it is associated wit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=8603936 |
| Source: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 4, 2022, pags. 26-35 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|
| id |
dialnet-ar-18-ART0001549010
|
|---|---|
| record_format |
dialnet
|
| institution |
Dialnet
|
| collection |
Dialnet AR
|
| source |
RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 4, 2022, pags. 26-35
|
| language |
Spanish
|
| topic |
Psoriasis
Terapias Biológicas Sistema Inmune Células T Citoquinas Multifactorial Dermatología Tratamiento Personalizado Psoriasis Biological Therapies Immune System T Cells Cytokines Multifactorial Dermatology Personalized Treatment |
| spellingShingle |
Psoriasis
Terapias Biológicas Sistema Inmune Células T Citoquinas Multifactorial Dermatología Tratamiento Personalizado Psoriasis Biological Therapies Immune System T Cells Cytokines Multifactorial Dermatology Personalized Treatment González Arreaga, Oscar Andrés Fienco Pérez, Adelma Yadira Noboa Avilés, Carla Ximena Vera Mendoza, Karla Julen Uso del Tratamiento Biológico en pacientes con Psoriasis |
| description |
Psoriasis is a chronic erythematous scaly disease of the skin, characterized by excessive hyperproliferation of epidermal keratinocytes and infiltration of the skin by inflammatory cells. Its cause is multifactorial: genetic predisposition triggered by an environmental stimulus, it is associated with other inflammatory diseases such as arthritis, inflammatory bowel disease and HIV infection. Biological treatments are indicated in the treatment of adult patients with moderate to severe psoriasis, patients with localized diseases, involving sites of high emotional impact such as: genitals, hands, feet, head and neck where it has a high functional and/or psychosocial impact. . Patients who previously received classical systemic treatment, including phototherapy, and who currently do not respond, have it contraindicated. Psori-asis treatment has evolved with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These drugs are designed to counteract specific components of the immune system, they are a major technological advance over tradi-tional immunosuppressive drugs and HIV infection. Biologic therapy is the use of agents that can specifically target an immune or genetic mediator of a pathophysiologic process. The introduction of these biological therapies has greatly improved the treatment of psoriasis. Biological agents interrupt the activation and migration of T cells. All with well-known adverse effects that require clinical and paraclinical monitoring. Therefore, to reduce the toxicity and side effects of treatment, rotational or sequential therapy between the different drugs is recommended. In search of an effective therapeutic alternative with a better safety profile than traditional immunosuppressive agents, since they involve a specific part of the immune system. A descriptive methodology was applied, with a documentary approach, that is, reviewing sources available on the network, with timely and relevant content to respond to what is discussed in this article
|
| format |
Article
|
| author |
González Arreaga, Oscar Andrés
Fienco Pérez, Adelma Yadira Noboa Avilés, Carla Ximena Vera Mendoza, Karla Julen |
| author_facet |
González Arreaga, Oscar Andrés
Fienco Pérez, Adelma Yadira Noboa Avilés, Carla Ximena Vera Mendoza, Karla Julen |
| author_sort |
González Arreaga, Oscar Andrés
|
| title |
Uso del Tratamiento Biológico en pacientes con Psoriasis
|
| title_short |
Uso del Tratamiento Biológico en pacientes con Psoriasis
|
| title_full |
Uso del Tratamiento Biológico en pacientes con Psoriasis
|
| title_fullStr |
Uso del Tratamiento Biológico en pacientes con Psoriasis
|
| title_full_unstemmed |
Uso del Tratamiento Biológico en pacientes con Psoriasis
|
| title_sort |
uso del tratamiento biológico en pacientes con psoriasis
|
| publishDate |
2022
|
| url |
https://dialnet.unirioja.es/servlet/oaiart?codigo=8603936
|
| _version_ |
1767464034471247872
|
| spelling |
dialnet-ar-18-ART00015490102023-05-30Uso del Tratamiento Biológico en pacientes con PsoriasisGonzález Arreaga, Oscar AndrésFienco Pérez, Adelma YadiraNoboa Avilés, Carla XimenaVera Mendoza, Karla JulenPsoriasisTerapias BiológicasSistema InmuneCélulas TCitoquinasMultifactorialDermatologíaTratamiento PersonalizadoPsoriasisBiological TherapiesImmune SystemT CellsCytokinesMultifactorialDermatologyPersonalized TreatmentPsoriasis is a chronic erythematous scaly disease of the skin, characterized by excessive hyperproliferation of epidermal keratinocytes and infiltration of the skin by inflammatory cells. Its cause is multifactorial: genetic predisposition triggered by an environmental stimulus, it is associated with other inflammatory diseases such as arthritis, inflammatory bowel disease and HIV infection. Biological treatments are indicated in the treatment of adult patients with moderate to severe psoriasis, patients with localized diseases, involving sites of high emotional impact such as: genitals, hands, feet, head and neck where it has a high functional and/or psychosocial impact. . Patients who previously received classical systemic treatment, including phototherapy, and who currently do not respond, have it contraindicated. Psori-asis treatment has evolved with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These drugs are designed to counteract specific components of the immune system, they are a major technological advance over tradi-tional immunosuppressive drugs and HIV infection. Biologic therapy is the use of agents that can specifically target an immune or genetic mediator of a pathophysiologic process. The introduction of these biological therapies has greatly improved the treatment of psoriasis. Biological agents interrupt the activation and migration of T cells. All with well-known adverse effects that require clinical and paraclinical monitoring. Therefore, to reduce the toxicity and side effects of treatment, rotational or sequential therapy between the different drugs is recommended. In search of an effective therapeutic alternative with a better safety profile than traditional immunosuppressive agents, since they involve a specific part of the immune system. A descriptive methodology was applied, with a documentary approach, that is, reviewing sources available on the network, with timely and relevant content to respond to what is discussed in this articleLa psoriasis es una enfermedad eritemato escamosa crónica de la piel, se caracteriza por la hiper proliferación de queratinocitos epidérmicos de forma excesiva e infiltración de la piel por células inflamatorias. Su causa es multifactorial: predisposición genética desencadenada por un estímulo medioambiental, se asocia a otras enfermedades inflamatorias como la artritis, enfermedad inflamatoria intestinal e infección por VIH. Los tratamientos biológicos están indicados en el tratamiento de pacientes adultos con psoriasis moderada a grave, pacientes con enfermedades localizadas, que involucran sitios de alto impacto emocional como: genitales, manos, pies, cabeza y cuello donde tiene una alta repercusión funcional y/o psicosocial. Pacientes que anteriormente recibieron tratamiento sistémico clásico, incluyendo fototerapia y que actualmente no responden, lo tienen contraindicado. El tratamiento de la psoriasis ha evolucionado gracias al advenimiento de las terapias biológicas, que incluyen infliximab, etanercept, adalimumab, efalizumab y alefacept. Estos medicamentos están diseñados para contrarrestar componentes específicos del sistema inmune, son un avance tecnológico importante sobre los medicamentos inmunosupresores tradicionales e infección por VIH. La terapia biológica es el uso de agentes que pueden dirigirse específicamente a un mediador inmune o genético de un proceso fisiopatológico. La introducción de estas terapias biológicas ha mejorado enormemente el tratamiento de la psoriasis. Los agentes biológicos interrumpen la activación y la migración de las células T. Todos con efectos adversos bien conocidos y que requieren monitoreo clínico y paraclínico. Por consiguiente, para disminuir la toxicidad y los efectos secundarios del tratamiento se recomienda realizar una terapia rotacional o secuencial entre los diferentes fár-macos. En busca de una alternativa terapéutica efectiva y con mejor perfil de seguridad que los agentes inmunosupresores tradicionales, ya que involucran una parte específica del sistema inmune. Se aplicó una metodología descriptiva, con un enfoque documental, es decir, revisar fuentes disponibles en la red, con contenido oportuno y relevante para dar respuesta a lo tratado en el presente artículo2022text (article)application/pdfhttps://dialnet.unirioja.es/servlet/oaiart?codigo=8603936(Revista) ISSN 2588-073XRECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 4, 2022, pags. 26-35spaLICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI
|